Wall Street Still To Assess Cardinal’s (CAH) Health

Barron’s feels that the Wall Street is yet to assess the projected strength of Cardinal Health, Inc. (NYSE: CAH). Cardinal is the second largest drug distributor in US. Barron’s lists out the positives for the company and for the drug distribution industry – which involves handling lots of cash. For Cardinal, in the current year – that should be about $ 1.2 billion.

Barron’s explains that after Cardinal sold CareFusion Corporation (NYSE: CFN), its stock shot up 19%. Cardinal is currently quoting at $ 29.5 a share. This could shoot up to $ 40 a share by next year – if Cardinal’s managers make and implement some sound strategies.

One way is to improve its margins – from the 0.92% earned currently by Cardinal. Many analysts like Josh Rothe, of SKBA Capital Management feel that more upside may be in store for the stock. Cardinal’s decisions like speeding up deliveries and improving profit mix may increase margins and profits.